C1 inhibitor deficiency: Management

Clinical and Experimental Dermatology

Volumn 30, Issue 6, 2005, Pages 737-740

  Compels, M M ^a   Lock, R J ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; CONTRACEPTIVE AGENT; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FRESH FROZEN PLASMA; OXANDROLONE; STANOZOLOL; TRANEXAMIC ACID;

ANGIONEUROTIC EDEMA; ARTICLE; CONSENSUS; CONTRACEPTION; DENTAL CARE; HORMONE SUBSTITUTION; HUMAN; INFECTION PREVENTION; PREGNANCY; PRIORITY JOURNAL; UNITED KINGDOM;

ADULT; ANGIONEUROTIC EDEMA; CHILD; CHILD, PRESCHOOL; COMPLEMENT C1 INACTIVATOR PROTEINS; EMERGENCY MEDICAL SERVICES; FEMALE; GREAT BRITAIN; HUMANS; MALE;

EID: 27144463432     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01936.x     Document Type: Article

References (17)

1. Compels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 39: 379-94.
2. Cicardi M, Bergamaschini L, Marasini B et al. Hereditary angioedema. an appraisal of 104 cases. Am J Med Sci 1982; 284: 2-9.
3. Fay A, Abinun M. Current management of hereditary angio-oedema (C′1 esterase inhibitor deficiency). J Clin Pathol 2002; 55: 266-70.
4. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Safety 2002; 25: 73-6.
5. Bork K, Siedlecki K, Bosch S et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75: 349-54.
6. Frank MM, Sergent JS, Kane MA et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double blind study. N Engl J Med 1972; 286: 808-12.
7. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema. the clinical syndrome and its management. Ann Intern Med 1976; 84: 580-93.
8. Kunschak M, Engl W, Maritsch F et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998; 38: 540-9.
9. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: 1630-4.
10. Bork K, Hardt J, Schicketanz KH et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 2003; 163: 1229-35.
11. Anonymous. Antifibrinolytic drugs and haemostatics. In: British National Formulary, 45th edn. Oxford: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2003:124.
12. Anthony PP. Liver tumours. Baillieres Clin Gastroenterol 1988; 2: 501-22.
13. Bork K, Pitton M, Harten P, Koch P. Hepatocelluar adenomas in patients taking danazol for hereditary angiooedema. Lancet. 1999; 353: 1066-7.
14. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002; 36: 707-9.
15. Cicardi M, Mannucci PM, Castelli R et al. Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion 1995; 35: 209-12.
16. Han FD, MacFarlane RC, Mulligan AN et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-63.
17. Wolff MW, Zhang F, Roberg JJ et al. Expression of C1 esterase inhibitor by the baculovirus expression vector system: preparation, purification, and characterization. Protein Expr Purif 2001; 22: 414-21.